BONS logo

Bonus BioGroup Ltd. Stock Price

TASE:BONS Community·₪269.8m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

BONS Share Price Performance

₪0.23
0.11 (89.34%)
₪0.23
0.11 (89.34%)
Price ₪0.23

BONS Community Narratives

There are no narratives available yet.

Snowflake Analysis

Moderate risk with worrying balance sheet.

5 Risks
1 Reward

Bonus BioGroup Ltd. Key Details

₪0

Revenue

₪0

Cost of Revenue

₪0

Gross Profit

₪25.5m

Other Expenses

-₪25.5m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.022
0%
0%
0%
View Full Analysis

About BONS

Founded
1981
Employees
37
CEO
Shai Meretzki
WebsiteView website
bonus-bio.com

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company’s products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients. It also develops MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS which is in phase III clinical trial, as well as in preclinical stage for the treatment of other inflammations and tissue damage, including chronic kidney diseases, osteoarthritis, and cytokine release syndrome. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is headquartered in Haifa, Israel.

Recent BONS News & Updates

Recent updates

No updates